ChromaDex Co. (NASDAQ:CDXC) CFO Ozan Pamir Buys 2,907 Shares

ChromaDex Co. (NASDAQ:CDXC - Get Free Report) CFO Ozan Pamir bought 2,907 shares of the business's stock in a transaction that occurred on Friday, November 22nd. The shares were bought at an average cost of $7.36 per share, with a total value of $21,395.52. Following the completion of the purchase, the chief financial officer now directly owns 2,907 shares of the company's stock, valued at $21,395.52. This represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.

ChromaDex Stock Up 0.3 %

NASDAQ CDXC traded up $0.02 during trading hours on Monday, hitting $7.46. 871,306 shares of the company were exchanged, compared to its average volume of 542,070. ChromaDex Co. has a 52 week low of $1.32 and a 52 week high of $7.85. The stock has a 50-day moving average price of $4.61 and a 200 day moving average price of $3.59. The stock has a market cap of $569.79 million, a PE ratio of 747.75 and a beta of 1.88.

ChromaDex (NASDAQ:CDXC - Get Free Report) last released its quarterly earnings results on Thursday, October 31st. The company reported $0.02 earnings per share for the quarter. ChromaDex had a return on equity of 4.85% and a net margin of 1.62%. The company had revenue of $25.58 million for the quarter, compared to analyst estimates of $23.70 million. During the same quarter in the prior year, the firm posted ($0.01) EPS. As a group, sell-side analysts anticipate that ChromaDex Co. will post 0.04 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on CDXC. StockNews.com lowered ChromaDex from a "strong-buy" rating to a "buy" rating in a research note on Monday, November 18th. HC Wainwright raised their target price on shares of ChromaDex from $6.00 to $8.00 and gave the company a "buy" rating in a report on Monday, November 4th. Finally, Roth Mkm upped their price target on shares of ChromaDex from $6.00 to $8.00 and gave the company a "buy" rating in a research note on Wednesday, November 6th.

Hedge Funds Weigh In On ChromaDex

Large investors have recently made changes to their positions in the company. Miracle Mile Advisors LLC purchased a new position in shares of ChromaDex during the second quarter valued at approximately $27,000. The Manufacturers Life Insurance Company purchased a new position in ChromaDex during the 2nd quarter valued at $31,000. Merriman Wealth Management LLC bought a new position in ChromaDex in the 2nd quarter valued at $32,000. Lazard Asset Management LLC purchased a new stake in ChromaDex in the first quarter worth $43,000. Finally, SG Americas Securities LLC bought a new stake in shares of ChromaDex during the first quarter worth $54,000. 15.41% of the stock is owned by hedge funds and other institutional investors.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.